Abstract:The Philadelphia chromosome is formed by a balanced, reciprocal translocation that pairs sequences from BCR on Chromosome 22 with sequences from ABL on Chromosome 9, resulting in the production of the constitutively active tyrosine kinase (TK) BCR-ABL. Depending on the location of the breakpoint within BCR, three different sizes of BCR-ABL may form, each associated with distinct clinical sequelae. Previous studies identified a functional domain within the BCR sequences preserved by the more-indolent forms of BCR-ABL (i.e., p210 and p230) that demonstrates a constitutive Rho guanine nucleotide exchange factor (RhoGEF) activity. Using the structurally derived S509A mutation, which does not affect TK activity but abrogates RhoGEF signaling, we, subsequently, showed that this feature regulates leukemia progression in mice. The RhoGEF domain was recently reported to contain two missense mutations (F547L and T654K) in a chronic myelogenous leukemia (CML) blast crisis (BC) patient, suggesting that it may play a role in human disease as well. To evaluate the clinical significance of this region, we, therefore, examined p210 BCR-ABL constructs containing these clinically derived RhoGEF mutations (CDRMs), both in isolation and in combination, using a murine bone marrow transplant (mBMT) model of CML. The mutations did not destabilize p210 BCR-ABL expression or TK activity but decreased RhoGEF signaling. Relative to mice transplanted with wild-type (WT) p210 BCR-ABL, those that received the CDRMs exhibited an earlier onset of disease, frequently developing previously unseen dermatologic involvement or myeloid sarcomas, but demonstrated significantly increased survival in an additive manner [Fig. 1]. While mice transplanted with WT p210 BCR-ABL exhibited neutrophilia that progresses to a less-differentiated phenotype at death, disease in the CDRM mice was characterized by eosinophilia and monocytosis with no maturation arrest. The most likely cause of death in mice transplanted with WT p210 BCR-ABL is widespread hematogenous involvement of the lungs resulting in acute respiratory distress. In contrast, mice receiving the CDRMs demonstrated pulmonary involvement which was limited to the bronchovascular bundles or subpleural space. This is consistent with a switch to lymphatogenous spread, likely secondary to skewed differentiation, and it implies an alternate cause(s) of death. To help determine the mechanism responsible for the observed differences in differentiation and maturation arrest, we next studied the CDRMs in vitro using the 32Dcl3 murine myeloid precursor cell line. A growing body of evidence suggests that the DNA damage response can affect lineage restriction in myeloid cells; it is also well-established that the accumulation of DNA damage is necessary for progression to BC. Accordingly, the CDRMs were associated with the restoration of p53 activation and the G1/S cell cycle checkpoint relative to WT p210 BCR-ABL. This suggests that the RhoGEF domain may be responsible for the suppression of the DNA damage response. Because the mBMT phenotype associated with the S509A mutation was distinct from that of the CDRMs, it may indicate that this capability is mediated by some functionality yet to be described. Importantly, the CDRMs were also associated with increased Src family kinase activity, which is thought to be a major mechanism of BCR-ABL-independent TK inhibitor resistance and minimal residual disease. Collectively, these results suggest that the BCR-ABL RhoGEF domain can influence disease progression and response to treatment in human leukemia. Disclosures No relevant conflicts of interest to declare.

Bcr-Abl with an SH3 Deletion Retains the Ability to Induce a Myeloproliferative Disease in Mice, Yet C-Abl Activated by an SH3 Deletion Induces Only Lymphoid Malignancy.

Bcr-Abl Has a Greater Intrinsic Capacity Than V-Abl to Induce the Neoplastic Expansion of Myeloid Cells

The NH2-Terminal Coiled-Coil Domain and Tyrosine 177 Play Important Roles in Induction of a Myeloproliferative Disease in Mice by Bcr-Abl

C-Cbl is Not Required for Leukemia Induction by Bcr-Abl in Mice

The Abl Carboxyl Terminal Region is Required for the Induction of Acute Lymphoblastic Leukemia by V-Abl but Not for the Induction of Myeloproliferative Disease by BCR/ABL or V-Abl.

Role of Phosphatidylinositol 3-Kinase and Specific Protein Kinase B Isoforms in the Suppression of Apoptosis Mediated by the Abelson Protein-tyrosine Kinase

The Coiled-Coil Domain And Tyr177 Of Bcr Are Required To Induce A Murine Chronic Myelogenous Leukemia-Like Disease By Bcr/Abl

Examination of Clinically-Derived p210 BCR/ABL Rhogef Mutations in a Murine Bone Marrow Transplantation Model of CML

Abelson Tyrosine Kinase Controls BCR Signalling and B‐cell Differentiation by Promoting B‐cell Metabolism

BCR/ABL Activates Rap1 and B-Raf to Stimulate the MEK/Erk Signaling Pathway in Hematopoietic Cells.

Bcr-Abl Promotes CML Cell Proliferation through the Suppression of PHLPP Expression.

Aberrant Activation of CaMKIIγ Accelerates Chronic Myeloid Leukemia Blast Crisis.

The Ralgef Pathway Contributes To The Pathogenesis Of Chronic Myelogenous Leukemia By Bcr/Abl

Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia

Lipocalin 2 is Required for Bcr-Abl-Induced Tumorigenesis

[Overexpression of Shp-2 is Associated with the Unlimited Growth and Apoptosis Resistance of P210 Bcr-Abl-mediated Chronic Myeloid Leukemia].

The N-terminal Domain of the Non-Receptor Tyrosine Kinase ABL Confers Protein Instability and Suppresses Tumorigenesis

Induction of Chronic Myeloid Leukemia in Mice.

RAG enhances BCR‐ABL1 ‐positive leukemic cell growth through its endonuclease activity in vitro and in vivo

Cooperation of BCR-ABL and AML1/MDS1/EVI1 in Blocking Myeloid Differentiation and Rapid Induction of an Acute Myelogenous Leukemia

Abi1 Gene Silencing by Short Hairpin RNA Impairs Bcr-Abl-induced Cell Adhesion and Migration in Vitro and Leukemogenesis in Vivo